Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGMG0201 vaccine for essential hypertension
ACTRN12617001192370Phase 2Completed
- Sponsor
- Avance Clinical
- Start
- Apr 2018
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of AGMG0201 in essential hypertension (3 arms), sponsored by Avance Clinical. Primary endpoint: Safety and tolerability. Started Apr 2018; status: completed.
02
Drugs
AGMG0201
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ACTRN12617001192370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001192370.